Chimeric IgG1 monoclonal antibody targeting EGFR (ERBB1); blocks ligand binding and receptor dimerization, inhibits downstream MAPK and PI3K/AKT signaling, and induces Fcγ-mediated ADCC.
Chimeric IgG1 monoclonal antibody against EGFR (ERBB1) that blocks ligand binding and receptor dimerization, inhibiting downstream MAPK and PI3K/AKT signaling to suppress tumor cell proliferation and survival; Fc region engages Fcγ receptors to induce NK cell–mediated ADCC.
YES
DIRECT
Fc region engages Fcγ receptors on NK cells to mediate ADCC against EGFR-expressing cells (and may also trigger CDC).
Chimeric IgG1 monoclonal antibody targeting EGFR (ERBB1); blocks ligand binding and receptor dimerization, inhibits downstream MAPK and PI3K/AKT signaling, and induces Fcγ-mediated ADCC.
Chimeric IgG1 monoclonal antibody against EGFR (ERBB1) that blocks ligand binding and receptor dimerization, inhibiting downstream MAPK and PI3K/AKT signaling to suppress tumor cell proliferation and survival; Fc region engages Fcγ receptors to induce NK cell–mediated ADCC.
NO
INDIRECT
Cetuximab binds EGFR on tumor cells; its Fc engages FCGR3A (CD16A) on NK cells to trigger ADCC against EGFR+ targets. FCGR3A-expressing cells act as effectors and are not killed by the drug.
Oral small-molecule tyrosine kinase inhibitor of ABL, PDGFR, and KIT; intended to suppress parallel/bypass RTK and tumor–stroma signaling.
ATP-competitive tyrosine kinase inhibitor of ABL (including BCR-ABL), PDGFR, and KIT; prevents kinase autophosphorylation and downstream MAPK and PI3K/AKT signaling, inhibiting proliferation and inducing apoptosis in oncogene-driven cells and suppressing PDGF-mediated tumor–stroma signaling.
YES
DIRECT
Imatinib binds the ATP site of ABL1/BCR‑ABL, blocking autophosphorylation and downstream MAPK/PI3K‑AKT survival signaling, leading to cell‑cycle arrest and apoptosis in ABL‑dependent (e.g., BCR‑ABL+) cells.
Oral small-molecule tyrosine kinase inhibitor of ABL, PDGFR, and KIT; intended to suppress parallel/bypass RTK and tumor–stroma signaling.
ATP-competitive tyrosine kinase inhibitor of ABL (including BCR-ABL), PDGFR, and KIT; prevents kinase autophosphorylation and downstream MAPK and PI3K/AKT signaling, inhibiting proliferation and inducing apoptosis in oncogene-driven cells and suppressing PDGF-mediated tumor–stroma signaling.
YES
DIRECT
Imatinib directly inhibits PDGFRA kinase activity, blocking autophosphorylation and downstream MAPK/PI3K-AKT signaling, leading to growth arrest and apoptosis in PDGFRA-dependent cells.
Oral small-molecule tyrosine kinase inhibitor of ABL, PDGFR, and KIT; intended to suppress parallel/bypass RTK and tumor–stroma signaling.
ATP-competitive tyrosine kinase inhibitor of ABL (including BCR-ABL), PDGFR, and KIT; prevents kinase autophosphorylation and downstream MAPK and PI3K/AKT signaling, inhibiting proliferation and inducing apoptosis in oncogene-driven cells and suppressing PDGF-mediated tumor–stroma signaling.
YES
DIRECT
Imatinib directly inhibits PDGFRβ kinase activity by binding the ATP site, blocking autophosphorylation and downstream MAPK and PI3K/AKT signaling, leading to growth arrest and apoptosis in PDGFR-driven cells.